Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) SEC filings page on Stock Titan provides access to the company’s public filings and related disclosures as they appear in the U.S. Securities and Exchange Commission’s EDGAR system. Mirum is a biopharmaceutical and rare disease company with approved therapies such as LIVMARLI, CHOLBAM and CTEXLI and a pipeline that includes volixibat, brelovitug and MRM-3379, as described in its press releases.
Through this page, users can review Mirum’s current and historical filings, including Form 8-K reports that describe material events. Recent 8-K filings have covered topics such as an Agreement and Plan of Merger and Reorganization to acquire Bluejay Therapeutics, associated private placement subscription agreements, and corporate updates on financial results. Other 8-K disclosures include receipt of a Paragraph IV Certification Notice Letter related to a generic version of LIVMARLI and press releases furnished as exhibits discussing quarterly results.
Stock Titan enhances these documents with AI-powered summaries designed to highlight the main points of lengthy filings. For example, AI summaries can help readers quickly understand key terms of merger agreements, private placement structures, or the implications of patent-related notices referenced in Mirum’s 8-Ks. Users can also monitor unregistered sales of equity securities and other capital markets activities described in the filings.
This page updates as new Mirum filings are posted to EDGAR, giving investors and researchers a structured way to follow regulatory disclosures alongside the company’s rare disease commercial and development programs. Forms such as 10-K, 10-Q and additional 8-Ks, when available, can be reviewed with AI-generated insights to assist in interpreting Mirum’s reporting.
Mirum Pharmaceuticals’ President and COO Peter Radovich reported new equity awards dated January 28, 2026. He received a stock option for 25,120 shares of common stock at an exercise price of $100.85 per share.
He was also granted 16,280 restricted stock units, each representing one share of common stock, vesting in three equal annual installments starting January 28, 2027. In addition, 34,500 performance restricted stock units tied to performance criteria that were determined met on January 28, 2026 will vest as follows: two-thirds on March 15, 2026 and the remaining one-third on March 15, 2027. All awards are reported as directly owned.
Mirum Pharmaceuticals, Inc. CEO and director Christopher Peetz reported new equity awards, including stock options and stock units granted on January 28, 2026. He received stock options for 67,000 shares at an exercise price of $100.85, vesting over four years starting one year after the vesting commencement date.
Peetz was also granted 43,500 restricted stock units, vesting in three equal annual installments on each anniversary of January 28, 2026. In addition, 75,000 previously granted performance restricted stock units had their performance criteria confirmed as met; two-thirds of these shares vest on March 15, 2026 and one-third on March 15, 2027. All reported derivative holdings are listed as directly owned.
Mirum Pharmaceuticals, Inc. insider Jolanda Howe filed a notice to sell restricted shares under Rule 144. The filing covers the proposed sale of 842 shares of common stock, with an aggregate market value of 81606.64, through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on NASDAQ.
The 842 shares were acquired on 01/23/2026 as restricted stock units vesting under a registered compensation plan for services to the issuer. The filing notes that 926 shares of common stock were sold on 01/22/2026 for gross proceeds of 86419.16, and that 51393574 shares of common stock were outstanding.
Mirum Pharmaceuticals, Inc. insider plans a modest stock sale under Rule 144. A holder has filed to sell 1,053 shares of Mirum common stock on NASDAQ through Morgan Stanley Smith Barney LLC, with an approximate sale date of 01/26/2026 and an aggregate market value of 102,056.76.
The 1,053 shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services rendered to Mirum. Over the past three months, the same seller disposed of 1,421 shares of common stock on 01/22/2026 for gross proceeds of 132,615.15. Shares outstanding were 51,393,574 at the time referenced.
Mirum Pharmaceuticals insider Peter Radovich has filed a Form 144 to sell 3,143 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 304,619.56, out of 51,393,574 shares outstanding.
The shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services to the issuer. The filing also notes that during the past three months Radovich sold 2,382 shares of common stock on 01/22/2026 for gross proceeds of 222,300.69.
Mirum Pharmaceuticals stockholder plans to sell recently vested shares. A person named Christopher Peetz filed a notice to sell 6,831 shares of Mirum Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on NASDAQ, with an aggregate market value of 662,060.52.
These shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services rendered to the issuer. The notice also reports that during the past three months, the same seller disposed of 7,098 shares of common stock for gross proceeds of 662,422.46.
Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt reported routine equity compensation activity. On January 23, 2026, 2,667 restricted stock units vested and converted into the same number of common shares at an exercise price of $0. On January 26, 2026, he sold 1,053 of these shares at $96.192 per share to cover tax withholding obligations linked to the vesting. After these transactions, he directly owns 43,741 shares of common stock and 2,666 restricted stock units, which continue to vest in equal annual installments through the three-year schedule that began January 23, 2024.
Mirum Pharmaceuticals’ president and COO Peter Radovich reported routine equity transactions. On January 23, 2026, 5,750 restricted stock units vested and were converted to 5,750 shares of common stock at an exercise price of $0, increasing his directly held common shares to 26,429.
On January 26, 2026, he sold 3,143 shares of common stock at $96.192 per share, mainly to cover tax withholding on the vesting. After these transactions, he directly owned 23,286 shares of Mirum common stock and 5,750 restricted stock units, which continue to vest in thirds on each anniversary of January 23, 2024.
Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity transactions. On January 23, 2026, 1,500 restricted stock units vested and converted into 1,500 shares of common stock at an exercise price of $0, increasing her directly held common stock to 4,542 shares.
On January 26, 2026, Howe sold 842 shares of Mirum common stock at $96.192 per share to cover tax withholding obligations tied to the RSU vesting. After these transactions, she directly owned 3,700 shares of common stock and 1,500 restricted stock units, which continue to vest in thirds annually from January 23, 2024.
Mirum Pharmaceuticals chief executive Christopher Peetz reported routine equity activity involving company stock. On January 23, 2026, he exercised 12,500 restricted stock units, each converting into one share of common stock at an exercise price of $0, increasing his direct holdings to 176,233 shares.
On January 26, 2026, Peetz sold 6,831 shares of common stock at $96.192 per share, with the filing stating these shares were sold to cover tax withholding tied to the RSU vesting. After the sale, he directly owned 169,402 shares and also beneficially owned 187,500 shares indirectly through The Peetz Family Trust.